<DOC>
	<DOCNO>NCT01473264</DOCNO>
	<brief_summary>Bronchopulmonary Dysplasia ( BPD ) multi-factorial disease process end result immature , surfactant deficient lung expose hyperoxia , mechanical ventilation infection . These condition initiate inflammatory response characterize elevated inflammatory cell infiltrate proinflammatory cytokine lead development significant acute chronic lung injury . The study drug , rhCC10 , recombinant version natural human CC10 protein . Native CC10 produce primarily non-ciliated respiratory epithelial cell , call Clara cell abundant protein mucosal fluid normal healthy lung . The purpose study evaluate pharmacokinetics , safety , tolerability anti-inflammatory effect single intratracheal ( IT ) dose rhCC10 intubated premature infant receive positive pressure ventilation treatment respiratory distress syndrome ( RDS ) prevent long term respiratory complication refer bronchopulmonary dysplasia , , recently , chronic respiratory morbidity ( CRM ; asthma , cough , wheeze , multiple respiratory infection ) . CC10 regulate inflammatory response protect structural integrity pulmonary tissue preserve pulmonary mechanical function various insult ( eg . viral infection , bacterial endotoxin , ozone , allergen , hyperoxia ) . Together property suggest administration rhCC10 may help facilitate development normal airway epithelia prevent inflammation lead CRM infant .</brief_summary>
	<brief_title>Safety , Pk Anti-inflammatory Effects CC10 Protein Premature Infants With Respiratory Distress Syndrome ( RDS )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Respiratory Distress Syndrome , Newborn</mesh_term>
	<mesh_term>Respiratory Distress Syndrome , Adult</mesh_term>
	<mesh_term>Bronchopulmonary Dysplasia</mesh_term>
	<criteria>Newborn infant consider study follow criterion meet : Age &lt; 24 hour ; Birthweight 700 1,300 gram ; Gestational age great equal 24 week ; Diagnosis neonatal RDS base clinical radiographic criterion ; Requiring intubation mechanical ventilation treatment RDS ; Received least one dose surfactant 100 mg/kg ( Survanta ; Ross Laboratories ) ; Written inform consent infant 's parent legal guardian prior enrollment patient agree studyrelated procedure evaluation , include require hospital discharge . â€¢ Major congenital abnormality ( chromosomal , genetic , cardiac , pulmonary , renal ) ;</criteria>
	<gender>All</gender>
	<minimum_age>24 Weeks</minimum_age>
	<maximum_age>29 Weeks</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>CC10</keyword>
	<keyword>BPD</keyword>
	<keyword>Bronchopulmonary dysplasia</keyword>
	<keyword>premature infant</keyword>
	<keyword>neonate</keyword>
	<keyword>pulmonary inflammation</keyword>
	<keyword>lung function</keyword>
	<keyword>RDS</keyword>
</DOC>